Neuphoria scraps social anxiety drug; Minerva doubles down on schizophrenia therapynews2025-10-21T15:03:33+00:00October 21st, 2025|Endpoints News|
GSK, Spero reveal full Phase 3 data for oral antibiotic, set for end-of-year filingnews2025-10-21T14:45:04+00:00October 21st, 2025|Endpoints News|
Updated: Novo Nordisk’s chair to step down; new board to focus on ‘faster decision-making’news2025-10-21T13:19:41+00:00October 21st, 2025|Endpoints News|
Chemify raises $50M+ Series B to scale molecule-making businessnews2025-10-21T12:00:17+00:00October 21st, 2025|Endpoints News|
CRISPR Therapeutics says its new gene editing tool is ‘a significant advance’ over prime editing. Prime Medicine disagreesnews2025-10-21T11:00:14+00:00October 21st, 2025|Endpoints News|
Galapagos to exit cell therapy, with loss of 365 jobs and global sites to shutternews2025-10-21T10:56:09+00:00October 21st, 2025|Endpoints News|
‘Decade of the ADCs’ continues as AstraZeneca, Kelun and Merck present data at #ESMO25news2025-10-21T09:15:27+00:00October 21st, 2025|Endpoints News|
Replimune resubmits melanoma drug for FDA approvalnews2025-10-20T19:31:08+00:00October 20th, 2025|Endpoints News|
Summit plans to take ivonescimab to FDA, even with subpar OS datanews2025-10-20T19:05:12+00:00October 20th, 2025|Endpoints News|
FDA staffing data show historic numbers of departures in fiscal 2025news2025-10-20T18:55:48+00:00October 20th, 2025|Endpoints News|
